|
1
|
Jonker JW, Suh JM, Atkins AR, Ahmadian M,
Li P, Whyte J, He M, Juguilon H, Yin YQ, Phillips CT, et al: A
PPARγ-FGF1 axis is required for adaptive adipose remodelling and
metabolic homeostasis. Nature. 485:391–394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu W, Struik D, Nies VJ, Jurdzinski A,
Harkema L, de Bruin A, Verkade HJ, Downes M, Evans RM, van Zutphen
T and Jonker JW: Effective treatment of steatosis and
steatohepatitis by fibroblast growth factor 1 in mouse models of
nonalcoholic fatty liver disease. Proc Natl Acad Sci USA.
113:2288–2293. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pearson-Stuttard J, Guzman-Castillo M,
Penalvo JL, Rehm CD, Afshin A, Danaei G, Kypridemos C, Gaziano T,
Mozaffarian D, Capewell S and O'Flaherty M: Modeling future
cardiovascular disease mortality in the United States: National
trends and racial and ethnic disparities. Circulation. 133:967–978.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Daugherty A, Tall AR, Daemen MJAP, Falk E,
Fisher EA, García-Cardeña G, Lusis AJ, Owens AP III, Rosenfeld ME,
Virmani R, et al: Recommendation on design, execution, and
reporting of animal atherosclerosis studies: A scientific statement
from the American heart association. Arterioscler Thromb Vasc Biol.
37:e131–e157. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brogi E, Winkles JA, Underwood R, Clinton
SK, Alberts GF and Libby P: Distinct patterns of expression of
fibroblast growth factors and their receptors in human atheroma and
nonatherosclerotic arteries. Association of acidic FGF with plaque
microvessels and macrophages. J Clin Invest. 92:2408–2418. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liau G, Winkles JA, Cannon MS, Kuo L and
Chilian WM: Dietary-induced atherosclerotic lesions have increased
levels of acidic FGF mRNA and altered cytoskeletal and
extracellular matrix mRNA expression. J Vasc Res. 30:327–332. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tordjman K, Bernal-Mizrachi C, Zemany L,
Weng S, Feng C, Zhang F, Leone TC, Coleman T, Kelly DP and
Semenkovich CF: PPARalpha deficiency reduces insulin resistance and
atherosclerosis in apoE-null mice. J Clin Invest. 107:1025–1034.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang L, Huang Z, Huang W, Chen X, Shan P,
Zhong P, Khan Z, Wang J, Fang Q, Liang G and Wang Y: Inhibition of
epidermal growth factor receptor attenuates atherosclerosis via
decreasing inflammation and oxidative stress. Sci Rep. 8:459172017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin Y, Bai L, Chen Y, Zhu N, Bai Y, Li Q,
Zhao S, Fan J and Liu E: Practical assessment of the quantification
of atherosclerotic lesions in apoE-/- mice. Mol Med Rep.
12:5298–5306. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sorci-Thomas MG and Thomas MJ:
Microdomains, inflammation, and atherosclerosis. Circ Res.
118:679–691. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pawlak M, Lefebvre P and Staels B:
Molecular mechanism of PPARα action and its impact on lipid
metabolism, inflammation and fibrosis in non-alcoholic fatty liver
disease. J Hepatol. 62:720–733. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Libby P, Ridker PM and Hansson GK:
Progress and challenges in translating the biology of
atherosclerosis. Nature. 473:317–325. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Raj T, Kanellakis P, Pomilio G, Jennings
G, Bobik A and Agrotis A: Inhibition of fibroblast growth factor
receptor signaling attenuates atherosclerosis in apolipoprotein
E-deficient mice. Arterioscler Thromb Vasc Biol. 26:1845–1851.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Beenken A and Mohammadi M: The FGF family:
Biology, pathophysiology and therapy. Nat Rev Drug Discov.
8:235–253. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cordon-Cardo C, Vlodavsky I,
Haimovitz-Friedman A, Hicklin D and Fuks Z: Expression of basic
fibroblast growth factor in normal human tissues. Lab Invest.
63:832–840. 1990.PubMed/NCBI
|
|
17
|
Sigala F, Savvari P, Liontos M, Sigalas P,
Pateras IS, Papalampros A, Basdra EK, Kolettas E, Papavassiliou AG
and Gorgoulis VG: Increased expression of bFGF is associated with
carotid atherosclerotic plaques instability engaging the NF-κB
pathway. J Cell Mol Med. 14:2273–2280. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin Z, Pan X, Wu F, Ye D, Zhang Y, Wang Y,
Jin L, Lian Q, Huang Y, Ding H, et al: Fibroblast growth factor 21
prevents atherosclerosis by suppression of hepatic sterol
regulatory element-binding protein-2 and induction of adiponectin
in mice. Circulation. 131:1861–1871. 2015. View Article : Google Scholar : PubMed/NCBI
|
